Memory Pharmaceuticals presents positive data for cognitive disorders drug

The results demonstrate that MEM 68626 is effective in models of cognition that are considered predictive of efficacy in Alzheimer’s disease and mild cognitive impairment. In addition, the data suggests the potential for once-daily oral dosing with a favorable safety and toxicology profile.

The results showed that MEM 68626 significantly enhanced object recognition in young rats, demonstrating improvements in both acquisition and consolidation memory processes in a model of episodic memory.

In a model of spatial reference memory, MEM 68626 restored cognitive function in aged-impaired rats, and this effect was maintained with longer-term dosing. The data suggests that MEM 68626 was active in the cortical and hippocampal areas of the brain, critical regions that are compromised in Alzheimer’s disease and MCI.

Pharmacokinetic studies of MEM 68626 demonstrated that the compound achieved plasma and brain exposure levels sufficient for once-a-day dosing.

Vaughn Kailian, president and CEO of Memory Pharmaceuticals, said: “MEM 68626 produces a robust effect in key models of cognition with a favorable safety and pharmacokinetic profile, providing a strong rationale for clinical development in a cognition indication. We look forward to advancing this program into the clinic by year-end.”